Literature DB >> 15185075

INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma.

Michael Vieth1, Regine Schneider-Stock, Knut Röhrich, Andrea May, Christian Ell, Anett Markwarth, Albert Roessner, Manfred Stolte, Andrea Tannapfel.   

Abstract

INTRODUCTION: The INK4a-ARF [CDKN2A]- locus on chromosome 9p21 encodes for two tumour suppressor proteins, p16INK4a and p14ARF, which act as upstream regulators of the Rb-CDK4 and p53 pathways. To study the contribution of each pathway to the carcinogenesis of Barrett's adenocarcinoma, we analysed the alterations of p14ARF and p16INK4a in preneoplastic and neoplastic lesions of this disease.
MATERIALS AND METHODS: After microdissection, DNA of 15 Barrett's adenocarcinomas, 40 Barrett's intraepithelial neoplasms (n=20 low- and n=20 high-grade) and 15 Barrett's mucosa without neoplasia was analysed for INK4-ARF inactivation using DNA sequence and loss of heterozygosity (LOH) analysis, methylation-specific polymerase chain reaction, restriction-enzyme-related polymerase chain reaction and immunohistochemistry.
RESULTS: We detected 9p21 LOH, p16INK4a methylation and p16INK4a mutations in Barrett's adenocarcinomas in 5 of 15 (33%), 8 of 15 (53%) and 1 of 15 (7%) patients, respectively. P14ARF was methylated in 3 of 15 (20%) adenocarcinomas. In Barrett's intraepithelial neoplasia, p16INK4a was altered in 12 of 20 (60%) high-grade and in 4 of 20 (20%) low-grade intraepithelial neoplasms. In Barrett's mucosa without intraepithelial neoplasia p16(INK4a) was methylated in one case (7%). P14ARF was intact in Barrett's mucosa without intraepithelial neoplasia.
CONCLUSIONS: We conclude that most Barrett's intraepithelial neoplasms contain genetic and/or epigenetic INK4a-ARF alterations. Methylation of p16INK4a appears to be the most frequent epigenetic defect in the neoplastic progression of Barrett's tumourigenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15185075     DOI: 10.1007/s00428-004-1042-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  45 in total

Review 1.  DNA mismatch repair genes and colorectal cancer.

Authors:  J M Wheeler; W F Bodmer; N J Mortensen
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

2.  Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus.

Authors:  P Sharma; A P Weston; M Topalovski; R Cherian; A Bhattacharyya; R E Sampliner
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Accelerated age-related CpG island methylation in ulcerative colitis.

Authors:  J P Issa; N Ahuja; M Toyota; M P Bronner; T A Brentnall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

Review 4.  Barrett's esophagus.

Authors:  S J Spechler
Journal:  Semin Oncol       Date:  1994-08       Impact factor: 4.929

5.  CpG island methylation in colorectal adenomas.

Authors:  A Rashid; L Shen; J S Morris; J P Issa; S R Hamilton
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

6.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

Review 7.  Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  M Pera
Journal:  Recent Results Cancer Res       Date:  2000

8.  CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.

Authors:  Joni L Rutter; Alisa M Goldstein; Michael R Dávila; Margaret A Tucker; Jeffery P Struewing
Journal:  Oncogene       Date:  2003-07-10       Impact factor: 9.867

9.  Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus.

Authors:  B Klump; C J Hsieh; K Holzmann; M Gregor; R Porschen
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

Review 10.  Barrett's esophagus, dysplasia, and adenocarcinoma.

Authors:  R C Haggitt
Journal:  Hum Pathol       Date:  1994-10       Impact factor: 3.466

View more
  10 in total

Review 1.  Epigenetic biomarkers in esophageal cancer.

Authors:  Andrew M Kaz; William M Grady
Journal:  Cancer Lett       Date:  2012-03-07       Impact factor: 8.679

2.  Claudin expression in Barrett's esophagus and adenocarcinoma.

Authors:  Hajnalka Gyõrffy; Agnes Holczbauer; Pál Nagy; Zsuzsa Szabó; Péter Kupcsulik; Csilla Páska; János Papp; Zsuzsa Schaff; András Kiss
Journal:  Virchows Arch       Date:  2005-08-30       Impact factor: 4.064

3.  Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression.

Authors:  Doerthe Kuester; Altaf A Dar; Christopher C Moskaluk; Sabine Krueger; Frank Meyer; Roland Hartig; Manfred Stolte; Peter Malfertheiner; Hans Lippert; Albert Roessner; Wael El-Rifai; Regine Schneider-Stock
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

4.  Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1.

Authors:  Nicholas J Clemons; Hongdo Do; Christina Fennell; Siddhartha Deb; Andrew Fellowes; Alexander Dobrovic; Wayne A Phillips
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

Review 5.  Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Andrew M Kaz; William M Grady; Matthew D Stachler; Adam J Bass
Journal:  Gastroenterol Clin North Am       Date:  2015-04-01       Impact factor: 3.806

6.  Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus.

Authors:  Rita Pinto; Tobias Hauge; Marine Jeanmougin; Heidi D Pharo; Stine H Kresse; Hilde Honne; Sara B Winge; May-Britt Five; Theresa Kumar; Tom Mala; Truls Hauge; Egil Johnson; Guro E Lind
Journal:  Clin Epigenetics       Date:  2022-06-14       Impact factor: 7.259

Review 7.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

8.  p16 mutation spectrum in the premalignant condition Barrett's esophagus.

Authors:  Thomas G Paulson; Patricia C Galipeau; Lianjun Xu; Heather D Kissel; Xiaohong Li; Patricia L Blount; Carissa A Sanchez; Robert D Odze; Brian J Reid
Journal:  PLoS One       Date:  2008-11-27       Impact factor: 3.240

9.  Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice.

Authors:  Jing Hao; Ba Liu; Chung S Yang; Xiaoxin Chen
Journal:  BMC Gastroenterol       Date:  2009-07-23       Impact factor: 3.067

10.  Progressive silencing of p14ARF in oesophageal adenocarcinoma.

Authors:  Yinghui Huang; Christopher J Peters; Rebecca C Fitzgerald; Ruth A Gjerset
Journal:  J Cell Mol Med       Date:  2008-04-09       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.